New pivotal trial data on EndeavorRx in adolescents ages 13-17 with ADHD released this morning. See topline results here in our release issued this morning:

We're no longer posting updates on Twitter. For the latest Akili news, please check out our blog, visit us on LinkedIn or sign up to have Akili news delivered to your inbox:

Akili leaders will speak at @Cowen_Inc 43rd Annual Health Care conference on March 8.

We loved talking about the #science behind #adhd with @SCFG! Learn more about how your brain gives you superpowers:

Akili plans to submit for EndeavorRxⓇ label expansion with FDA in 2023 to potentially make the video game treatment available for kids 8-17 years old.

We’re taking you behind the scenes of the work we’re doing to advance the field of #cognitivescience. Read more in our blog post:

Kids deserve better. Our new Chief Medical Officer, @skollins1, writes about the need to challenge the status quo within #ADHD care management. Read more:

Excited to be attending the Solebury 1x1 Management Access event happening alongside the JP Morgan Healthcare Conference #JPM23. Can't wait to be back in person in San Francisco next month!

We'll discuss the relationship between objective measures of attention and academic performance in children with ADHD at #PsychUpdateWinter22

Today and tomorrow, we're presenting a poster at @Medscape's Psychiatry Update. Check out our oral presentation at 10:40am PT today and our poster session at 6:45pm PT on Friday, 12/2.

We're thrilled to announce that @skollins1 has joined Akili as Chief Medical Officer. His experience with innovative approaches to ADHD treatment will be invaluable as we work to deliver for patients and their families every day. https://t.co/lg4WUQaTw7

Our COO recently spoke with @MassDevice podcast, @DeviceTalks, about his career and work to scale our flagship product. Listen here:

We're wrapping up the last day of @CHADD_ADHD #ADHD2022 at Booth 102 and the Relaxicus Retreat. Come check out an interactive demo and learn more!

"The status of our ADHD care management is unacceptable, and it has been for a very long time...Our innovation in treatment and diagnosis has stagnated for years. We need something new; something different." - @skollins1 at #ADHD2022 @CHADD_ADHD

@CHADD_ADHD If you need to recharge at any point, swing by our Relaxicus Retreat lounge on the show floor!

We're in Dallas today kicking off @CHADD_ADHD's Annual International Conference. Members of our team will be hosting focus groups, roundtables, and giving hands-on demos of our flagship product at Booth 102.

We’re honored to receive the @ucsfhealthhub’s Digital Health Awards Best in Class Award in the Mental and Behavioral Health category. A mental health emergency impacting our nation’s youth was declared a year ago, and patients need new, non-drug treatment options.

We're at #OMTechnology today, speaking about harnessing the power of digital therapeutics (#DTx) in pediatrics. We'll see you there at 9:15am PT! @openmindscircle

We're honored to be among the list of amazing innovators recognized by @GalienFdn for their work to improve the lives of patients around the world.

We’re committed to continuing to challenge the status quo with digital treatments that improve cognition while bringing joy to patients.